Patent US4297238A successfully refreshed from Google Patents.
US4297238A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hemolysing solution preparing hemolysed blood having a stabilized glucose content
Assignee: Merck Patent GmbH
•
Filing: 1979-11-21
•
Granted: 1981-10-27
•
Expires: 1999-11-21
Abstract
Abstract A hemolysing solution for use in the determination of glucose in a whole blood sample which comprises (a) a buffer providing a pH of about 6-8, (b) sodium chloride, (c) a surface active agent and, (d) a chelating agent which in the presence of component (c) serves as a stabilizer against glycolysis in the hemolysate obtained by contacting the blood sample with said hemolysing solution.
Inventors
- 👤 Rolf Vormbrock
- 👤 Roland Helger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:31
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/66; C; C12; C12Q; C12Q1/00; C12Q1/54; Y; Y10; Y10T; Y10T436/00; Y10T436/10; Y10T436/107497; Y10T436/14; Y10T436/142222; Y10T436/143333; Y10T436/144444; Y10T436/25; Y10T436/2525
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
106 words
In a hemolysing solution used in the determination of glucose in a whole blood sample, consisting essentially of a lysing reagent and a glycolysis inhibitor which inhibits glycolysis in the hemolysate obtained by contacting the blood sample with the hemolysing solution, the improvement wherein the hemolysing solution consists essentially of (a) a buffer providing a pH of about 6-8; (b) 0.8-3.0 moles/liter of sodium chloride; (c) 1-4 g/l of a surface active agent; (d) 0.5-2 g/l of a chelating agent which in the presence of component (c) serves as a stabilizer against glycolysis in the hemolysate; and, optionally, (e) an effective amount of an antimicrobial agent.
Claim 2
Dependent Claim
106 words
In a hemolysing solution used in the determination of glucose in a whole blood sample, consisting essentially of a lysing reagent and a glycolysis inhibitor which inhibits glycolysis in the hemolysate obtained by contacting the blood sample with the hemolysing solution, the improvement wherein the hemolysing solution consists essentially of (a) a buffer providing a pH of about 6-8; (b) 0.8-3.0 moles/liter of sodium chloride; (c) 1-4 g/l of a surface active agent; (d) 0.5-2 g/l of a chelating agent which in the presence of component (c) serves as a stabilizer against glycolysis in the hemolysate; and, optionally, (e) an effective amount of an antimicrobial agent.
Claim 3
Dependent Claim
15 words
A hemolysing solution of claim 1, wherein the surface-active agent is a non-ionic surface-active agent.
Claim 4
Dependent Claim
15 words
A hemolysing solution of claim 2, wherein the surface-active agent is an alkylphenol polyglycol ether.
Claim 5
Dependent Claim
18 words
A hemolysing solution of claim 1, wherein the chelating agent is ethylenediaminetetraacetate, nitrilotriacetate, cyclohexylene-1,2-dinitrilotetraacetate, diethylenetriaminepentaacetate or bis-(aminoethyl)-glycol ether-N,N,N',N'-tetraacetate.
Claim 6
Dependent Claim
14 words
A hemolysing solution of claim 1 additionally comprising sodium azide as an antimicrobial agent.
Claim 7
Dependent Claim
28 words
A method for hemolysing whole blood and for stabilizing the concentration of glucose in the hemolysate, comprising treating whole blood with the aqueous hemolysing solution of claim 1.
Claim 8
Dependent Claim
28 words
The hemolysing solution of claim 1, wherein the surface active agent is an alkylphenol polyglycol ether and the chelating agent is ethylenediaminetetraacetate, nitrilotriacetate, cyclohexylene-1,2-dinitrilotetraacetate, diethylenetriaminepentaacetate or bis-(aminoethyl)-glycol ether-N,N,N',N'-tetraacetate.
References Cited (Backward Citations)
US3519572A
Cited
US3918905A
Cited
US3874851A
Cited
US3977995A
Cited
US3962125A
Cited
US4102810A
Cited
US3964865A
Cited
US4185964A
Cited
US4142857A
Cited
US4200435A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-10-26 | 1985-04-27 | 1985-10-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-10-26 | 1989-04-27 | 1989-10-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-10-26 | 1993-04-27 | 1993-10-27 | $7700.00 | Window Closed / Lapsed |